Patent SG-11201805594P-A (SG)
Title: Formulations for treating bladder cancer
Inventor: BETAGERI GURU
IPC: A61P35/00
Filed: 2017-01-09
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111011101011111101111011101111101111011111 International Bureau ... ..... ..Y1 j (10) International Publication Number (43) International Publication Date ..... .....!;,„. WO 2017/120586 Al 13 July 2017 (13.07.2017) WI P0 I P CT (51) International Patent Classification: (72) Inventors: BETAGERI, Guru, V.; 17325 Eastview Drive, A61P 35/00 (2006.01) A61K 31/337 (2006.01) Chino Hills, CA 91709 (US). VENKATESAN, Natara- A61K 31/282 (2006.01) A61K 9/127 (2006.01) jan; 1850 S. Diamond Bar Blvd., Apt. 509, Diamond Bar (21) International Application Number: 91765 CA (IN). OEFELEIN, Michael, G.; 3302 Laviana PCT/US2017/012720 Street, Tustin, CA 92782 (US). (22) International Filing Date: (74) Agent: GUNNELS, Zarema, E.; J.A. Lindeman & Co., 9 January 2017 (09.01.2017) PLLC, 3190 Fairview Park Drive, Suite 480, Falls Church, VA 22042 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind AO, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, 62/275,936 7 January 2016 (07.01.2016) US DO, 62/275,941 7 January 2016 (07.01.2016) US HN, 62/421,137 11 November 2016 (11.11.2016) US KP, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicants: WESTERN UNIVERSITY OF HEALTH MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, SCIENCES [US/US]; 309 E. Pomona Street, Pomona, CA NI, 91766 (US). TESORX PHARMA, LLC [US/US]; 3670 RU, West Temple Avenue, Suite 270, Pomona, CA 91768 TH, (US). ZA, ZM, ZW. NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, _ — = TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [Continued on next page] = (54) Title: FORMULATIONS FOR TREATING BLADDER CANCER (57) : Compositions and methods for making = and using proliposomal and liposomal formulations of Mean Tumor area after 14 days of treatment measured using histological method chemotherapeutic agents are disclosed. The prolipo - somal and liposomal formulations of chemotherapeut- 60 ics, as well as medicaments and dosage forms that in- _ = dude such formulations, can be used with treatment = so _ regimens for bladder cancer and urothelial cancer. \" E Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder can- = cers by intravesical administration and to treat ur- = 0 ao othelial cancers. The formulations according to the in- § vention include (a) a taxane (e.g., paclitaxel, do- = ''.' 20 to 2 cetaxel) or cisplatin, (b) a first phospholipid, dip- almitoyl phosphatidylcholine (DMPC), and (c) a — 10 second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle. _ 4' ,, 4 1, i '0 1-1 GO kin ei ,-1 1? ?, l k el, e. te.• I.. .. ` Fig. 6 IN ,-1 © ei O WO 2017/120586 Al MIDEDIM011111 11111111MEMEM111111011111111111111110111111111111 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, Published: LU, LV, MC, MK, MT, SI, SK, SM, TR), OAPI GN, GQ, GW, KM, ML, NL, (BF, MR, NE, NO, BJ, PL, PT, RO, RS, CF, CG, CI, CM, SN, TD, TG). SE, GA, with international search 21(3)) report (Art.